Nelson Sean A, Richards Katherine A, Glover Maryah A, Chaves Francisco A, Crank Michelle C, Graham Barney S, Kanekiyo Masaru, Sant Andrea J
David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
NPJ Vaccines. 2022 Oct 26;7(1):124. doi: 10.1038/s41541-022-00547-0.
Nanoparticle vaccines based on H. pylori ferritin are increasingly used as a vaccine platform for many pathogens, including RSV, influenza, and SARS-CoV-2. They have been found to elicit enhanced, long-lived B cell responses. The basis for improved efficacy of ferritin nanoparticle vaccines remains unresolved, including whether recruitment of CD4 T cells specific for the ferritin component of these vaccines contributes to cognate help in the B cell response. Using influenza HA-ferritin nanoparticles as a prototype, we have performed an unbiased assessment of the CD4 T cell epitope composition of the ferritin particles relative to that contributed by influenza HA using mouse models that express distinct constellations of MHC class II molecules. The role that these CD4 T cells play in the B cell responses was assessed by quantifying follicular helper cells (T), germinal center (GC) B cells, and antibody secreting cells. When mice were immunized with equimolar quantities of soluble HA-trimers and HA-Fe nanoparticles, HA-nanoparticle immunized mice had an increased overall abundance of T that were found to be largely ferritin-specific. HA-nanoparticle immunized mice had an increased abundance of HA-specific isotype-switched GC B cells and HA-specific antibody secreting cells (ASCs) relative to mice immunized with soluble HA-trimers. Further, there was a strong, positive correlation between CD4 T abundance and GC B cell abundance. Thus, availability of helper CD4 T cell epitopes may be a key additional mechanism that underlies the enhanced immunogenicity of ferritin-based HA-Fe-nanoparticle vaccines.
基于幽门螺杆菌铁蛋白的纳米颗粒疫苗越来越多地被用作包括呼吸道合胞病毒(RSV)、流感和严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在内的多种病原体的疫苗平台。已发现它们能引发增强的、持久的B细胞反应。铁蛋白纳米颗粒疫苗效力提高的基础仍未明确,包括这些疫苗中铁蛋白成分特异性CD4 T细胞的募集是否有助于B细胞反应中的同源辅助。我们以流感血凝素(HA)-铁蛋白纳米颗粒为原型,使用表达不同组合的II类主要组织相容性复合体(MHC)分子的小鼠模型,对铁蛋白颗粒相对于流感HA所贡献的CD4 T细胞表位组成进行了无偏倚评估。通过量化滤泡辅助性T细胞、生发中心(GC)B细胞和抗体分泌细胞,评估了这些CD4 T细胞在B细胞反应中所起的作用。当用等摩尔量的可溶性HA三聚体和HA-铁纳米颗粒免疫小鼠时,HA纳米颗粒免疫的小鼠中T细胞的总体丰度增加,且发现这些T细胞在很大程度上是铁蛋白特异性的。相对于用可溶性HA三聚体免疫的小鼠,HA纳米颗粒免疫的小鼠中HA特异性同种型转换的GC B细胞和HA特异性抗体分泌细胞(ASC)的丰度增加。此外,CD4 T细胞丰度与GC B细胞丰度之间存在强正相关。因此,辅助性CD4 T细胞表位的可用性可能是基于铁蛋白的HA-铁纳米颗粒疫苗免疫原性增强的一个关键附加机制。